Commentary - (2025) Volume 12, Issue 5
Received: 02-Oct-2025, Manuscript No. bset-26-181398;
Editor assigned: 05-Oct-2025, Pre QC No. P-181398;
Reviewed: 19-Oct-2025, QC No. Q-181398;
Revised: 23-Oct-2025, Manuscript No. R-181398;
Published:
30-Oct-2025
, DOI: 10.37421/2952-8526.2025.12.275
Citation: Schmidt, Anja B.. ”Advanced Techs Transform Cancer Care: Personalized Approaches.” J Biomed Syst Emerg Technol 12 (2025):275.
Copyright: © 2025 Schmidt B. Anja This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.
Precision oncology represents a paradigm shift in cancer care, moving away from one-size-fits-all approaches towards individualized treatment strategies tailored to the unique molecular and clinical characteristics of each patient. This evolution is heavily reliant on the integration of diverse data sources and sophisticated analytical tools. Advanced biomedical systems are at the forefront of this revolution, enabling a deeper understanding of cancer biology and facilitating the development of more effective therapies. One of the key pillars of precision oncology is the integration of multi-omics data, including genomics, transcriptomics, proteomics, and metabolomics, alongside imaging and clinical information. These comprehensive datasets allow for the identification of specific molecular alterations that drive cancer growth and progression, thereby pinpointing actionable targets for therapeutic intervention. Sophisticated computational platforms are essential for processing and interpreting this vast amount of data, aiding in the prediction of treatment response in individual patients [1].
Liquid biopsies have emerged as a transformative biomedical system, offering a non-invasive method for detecting and monitoring cancer. By analyzing circulating tumor DNA (ctDNA) and other biomarkers in bodily fluids such as blood, liquid biopsies provide valuable insights into tumor genetics, enabling early diagnosis, guiding treatment selection, and detecting the emergence of drug resistance. Advances in next-generation sequencing and digital PCR have significantly enhanced the sensitivity and accuracy of these methods, streamlining personalized cancer management [2].
Organ-on-a-chip technologies represent another significant advancement in biomedical systems for precision oncology. These microfluidic devices are designed to mimic the complex microenvironment and physiological functions of human organs, providing more predictive preclinical models than traditional cell cultures. This allows for patient-specific drug screening and the identification of effective therapies before their administration in clinical settings, reducing the risk of ineffective treatments [3].
Advanced imaging techniques, including positron emission tomography/magnetic resonance imaging (PET/MRI) and artificial intelligence (AI)-driven image analysis, are becoming indispensable tools in modern precision oncology. These biomedical systems facilitate precise tumor localization, detailed characterization of the tumor microenvironment, and accurate assessment of treatment response at a cellular level. The integration of quantitative imaging biomarkers with genomic data offers a comprehensive perspective for tailoring treatment strategies [4].
Wearable sensors and remote monitoring systems are increasingly being adopted as biomedical systems in precision oncology to gather real-time data on patient-reported outcomes and physiological parameters. These devices enable continuous monitoring, allowing for the early detection of treatment-related side effects, assessment of treatment adherence, and timely personalized interventions. This approach not only enhances patient engagement but also provides crucial support for survivorship care [5].
Single-cell technologies are driving significant progress in understanding tumor heterogeneity, a major challenge in cancer treatment. By analyzing individual cells, these biomedical systems provide unprecedented resolution to uncover the mechanisms underlying drug resistance and identify rare cell populations, such as cancer stem cells and circulating tumor cells. This granular level of insight is crucial for designing more effective and personalized treatment strategies [6].
Artificial intelligence (AI) and machine learning (ML) are fundamental biomedical systems that are revolutionizing precision oncology. These algorithms are employed for predictive modeling of treatment response, accelerating drug discovery, and interpreting complex multi-omics data. AI/ML tools assist in identifying specific patient subgroups who are most likely to benefit from particular therapies, thereby personalizing care pathways and optimizing treatment outcomes [7].
Three-dimensional (3D) bioprinting is emerging as a key biomedical system with substantial implications for precision oncology. This technology allows for the creation of functional tissues and organs, including patient-specific tumor models. These models can be utilized for high-throughput drug screening and for gaining a better understanding of individual treatment responses in a more physiologically relevant context, paving the way for highly personalized therapeutic development [8].
CRISPR-based gene editing technologies are rapidly advancing as powerful biomedical systems for precision oncology. These tools enable precise modification of cancer cell genomes, facilitating the development of personalized immunotherapies, correction of disease-causing mutations, and the creation of sophisticated preclinical models for studying tumor biology and therapeutic resistance. This precise genetic manipulation holds immense promise for developing novel cancer treatments [9].
The intricate landscape of precision oncology is continually shaped by the development and application of advanced biomedical systems. These systems are designed to provide a deeper understanding of cancer at an individual level, enabling tailored therapeutic interventions. Multi-omics data integration, coupled with sophisticated computational platforms, forms the bedrock of precision oncology, allowing for the identification of unique molecular targets and the prediction of treatment efficacy in specific patients. This approach aims to maximize therapeutic benefit while minimizing adverse effects [1].
Liquid biopsies exemplify the innovative application of biomedical systems in oncology. Their non-invasive nature allows for frequent monitoring of cancer progression and response to treatment through the analysis of circulating biomarkers. The advancements in next-generation sequencing and digital PCR technologies have made liquid biopsies highly sensitive tools for detecting genetic alterations associated with cancer, contributing to earlier diagnosis and more informed treatment choices. This technology significantly streamlines the process of personalized cancer management [2].
Organ-on-a-chip technologies are revolutionizing preclinical drug testing and personalized medicine in oncology. By recapitulating the complex architecture and function of human organs, these microfluidic devices offer a more accurate representation of in vivo conditions compared to traditional cell cultures. This enhanced predictive capability allows for more efficient and reliable patient-specific drug screening, ensuring that therapies are effective before they are administered to patients [3].
Advanced imaging techniques, including PET/MRI and AI-powered image analysis, are integral components of precision oncology. These biomedical systems offer unparalleled precision in tumor localization and characterization, providing critical insights into the tumor microenvironment and the effectiveness of therapies at a cellular level. The fusion of quantitative imaging biomarkers with genomic data provides a comprehensive picture essential for designing individualized treatment plans [4].
Wearable sensors and remote monitoring systems are increasingly being utilized as biomedical systems to enhance patient care in precision oncology. These devices collect real-time data on patient-reported outcomes and physiological health, enabling prompt identification of treatment side effects and adherence issues. This continuous feedback loop facilitates timely personalized interventions and improves the overall patient experience and survivorship care [5].
Single-cell technologies represent a groundbreaking advancement in biomedical systems for dissecting tumor heterogeneity. By allowing the analysis of individual cells, these technologies unveil the complex cellular composition of tumors and identify rare but critical cell populations, such as cancer stem cells and circulating tumor cells. This detailed cellular analysis is vital for understanding mechanisms of drug resistance and discovering new therapeutic targets, essential for precision treatment design [6].
Artificial intelligence (AI) and machine learning (ML) are pivotal biomedical systems driving innovation across precision oncology. Their capabilities in predictive modeling, drug discovery, and the interpretation of complex biological data are invaluable. AI/ML algorithms help clinicians identify patient subgroups most likely to respond to specific treatments, thereby optimizing therapeutic strategies and personalizing patient care pathways [7].
Three-dimensional (3D) bioprinting is emerging as a significant biomedical system with the potential to transform cancer modeling and drug discovery. The ability to fabricate patient-specific tumor models using 3D bioprinting offers a more physiologically relevant platform for high-throughput drug screening. This technology aids in predicting individual treatment responses and understanding tumor biology in a personalized context [8].
CRISPR-based gene editing technologies are becoming powerful biomedical systems in precision oncology. Their ability to precisely modify cancer cell genomes opens avenues for developing novel personalized immunotherapies and correcting genetic defects. Furthermore, these technologies are crucial for creating advanced preclinical models that aid in studying tumor behavior and resistance mechanisms, contributing to the development of more targeted therapies [9].
Proteomics, as a sophisticated biomedical system, plays a critical role in identifying and validating novel therapeutic targets and biomarkers within the context of precision oncology. Advanced mass spectrometry techniques enable comprehensive analysis of protein expression within tumors, revealing intricate patterns and post-translational modifications that influence cancer development and treatment response. This detailed protein-level information is essential for developing truly personalized treatment approaches [10].
Precision oncology is rapidly advancing due to sophisticated biomedical systems that enable personalized treatment strategies. These systems integrate multi-omics data, imaging, and clinical information to identify actionable targets and predict treatment response. Liquid biopsies offer non-invasive cancer detection and monitoring. Organ-on-a-chip technologies provide predictive preclinical models for drug testing. Advanced imaging techniques aid in tumor characterization and treatment assessment. Wearable sensors facilitate remote monitoring and patient engagement. Single-cell technologies unravel tumor heterogeneity and resistance mechanisms. Artificial intelligence and machine learning drive predictive modeling and drug discovery. 3D bioprinting creates patient-specific tumor models for drug screening. CRISPR gene editing enables precise genome modification for novel therapies. Proteomics identifies therapeutic targets and biomarkers. Collectively, these technologies are transforming cancer care towards more effective and individualized approaches.
None
None
